GlassScriptPhysician profile
Christian D Clark
NPI 1649223710
$7,311.19
in general payments reported to CMS, 2019-2025
30 companies · $590 in 2025
The $590 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $727 · 2021: $2,469 · 2022: $1,191 · 2023: $1,073 · 2024: $644 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,797.55 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $618.94 | 2019-2024 | Stelara, Simponi Aria, Remicade |
| Olympus America INC. | $608.41 | 2019-2023 | Evis Exera Lll Colonovideoscope, Endoclot Phs |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $532.43 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $514.45 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $438.84 | 2019-2025 | |
| Ambu INC. | $220.93 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $189.24 | 2022-2025 | Dupixent |
| Celgene Corporation | $171.82 | 2022-2024 | Zeposia |
| Covidien LP | $161.45 | 2019-2020 | |
| Gilead Sciences, INC. | $161.43 | 2019-2024 | |
| Lilly USA, LLC | $129.86 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $124.51 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $114.22 | 2021-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $83.53 | 2021-2023 | Rebyota |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $77.65 | 2021-2025 | Gi Genius, Interstim |
| Braintree Laboratories, INC. | $62.78 | 2021-2023 | Sutab |
| Genzyme Corporation | $52.81 | 2022-2023 | |
| Madrigal Pharmaceuticals | $46.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $38.82 | 2024-2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $34.80 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $29.59 | 2023-2024 | Ocaliva |
| Mylan Institutional INC. | $19.89 | 2023 | Hulio |
| Ironwood Pharmaceuticals, INC | $16.50 | 2024 | |
| Redhill Biopharma INC. | $16.24 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.91 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.78 | 2022 | |
| Boston Scientific Corporation | $11.19 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $10.13 | 2024 | Lesionhunter |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,097.44 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.